Michael M. Woll

Most-cited papers

1. Combined Clinical Trial Results of a HER2/neu (E75) Vaccine for the Prevention of Recurrence in High-Risk Breast Cancer Patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02

   G. Peoples, J. Holmes, M. Hueman, E. Mittendorf +10 more

   2008Clinical Cancer Research188 citations

   Semantic Scholar

   Save

2. Phase I Clinical Trial of a HER-2/neu Peptide (E75) Vaccine for the Prevention of Prostate-Specific Antigen Recurrence in High-Risk Prostate Cancer Patients

   M. Hueman, Z. A. Dehqanzada, T. Novak, JenniferM. Gurney +8 more

   2005Clinical Cancer Research58 citations

   Semantic Scholar

   Save

3. Direct Measurement of Peptide-Specific CD8+ T Cells Using HLA-A2:Ig Dimer for Monitoring the In Vivo Immune Response to a HER2/neu Vaccine in Breast and Prostate Cancer Patients

   Michael M. Woll, C. Fisher, G. Ryan, JenniferM. Gurney +7 more

   2004Journal of Clinical Immunology38 citations

   Semantic Scholar

   Save

4. Longterm followup assessment of a HER2/neu peptide (E75) vaccine for prevention of recurrence in high-risk prostate cancer patients.

   J. D. Gates, M. Carmichael, Linda C. Benavides, J. Holmes +7 more

   2009Journal of the American College of Surgeons21 citations

   Semantic Scholar

   Save

5. Preclinical testing of a peptide-based, HER2/neu vaccine for prostate cancer.

   Michael M. Woll, M. Hueman, G. Ryan, C. Ioannides +6 more

   2004International Journal of Oncology11 citations

   Semantic Scholar

   Save

6. Bilateral Spontaneous Dissection of the Internal Carotid Arteries

   Michael M. Woll, J. Goff, D. Gillespie, S. L. Minken

   2001Vascular and Endovascular Surgery10 citations

   Semantic Scholar

   Save

7. Surgical Critical Care for the Trauma Patient with Cardiac Disease.

   Michael M. Woll, L. Maerz

   2016Anesthesiology Clinics3 citations

   Semantic Scholar

   Save

8. Phase IClinical Trial of a HER-2 / neu Peptide ( E 75 ) Vaccine for the Prevention of Prostate-Specific Antigen Recurrence in High-Risk Prostate Cancer Patients

   M. Hueman, Z. A. Dehqanzada, T. Novak, JenniferM. Gurney +8 more

   20051 citations

   Semantic Scholar

   Save

9. A more sensitive immunological monitoring tool for cancer vaccine trials: A direct comparison of HLA-A2 dimer and tetramer molecules in measuring the in vivo immune response to a HER2/neu peptide-based vaccine (E75) in prostate and breast cancer patients

   M. Hueman, JenniferM. Gurney, Michael M. Woll, C. Storrer +4 more

   20041 citations

   Semantic Scholar

   Save

10. Combined ClinicalTrial Results of a HER2/neu (E75) Vaccine for the Prevention of Recurrence in High-Risk Breast Cancer Patients: U.S. Military Cancer Institute ClinicalTrials Group Study I-01and I-02

    G. Peoples, J. Holmes, M. Hueman, E. Mittendorf +10 more

    20080 citations

    Semantic Scholar

    Save

11. Clinical trial results of a HER2/neu peptide (E75) vaccine in preventing recurrence in node positive breast cancer patients

    M. Hueman, JenniferM. Gurney, Michael M. Woll, C. Storrer +6 more

    20040 citations

    Semantic Scholar

    Save